- Home
- INZY vs ACHV Comparison
INZY vs ACHV Comparison
Compare INZY & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- ACHV
- Stock Information
- Founded
- INZY 2015
- ACHV N/A
- Country
- INZY United States
- ACHV Canada
- Employees
- INZY N/A
- ACHV N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- INZY Health Care
- ACHV Health Care
- Exchange
- INZY Nasdaq
- ACHV Nasdaq
- Market Cap
- INZY 64.9M
- ACHV 72.5M
- IPO Year
- INZY 2020
- ACHV N/A
- Fundamental
- Price
- INZY $3.97
- ACHV $3.58
- Analyst Decision
- INZY Buy
- ACHV Strong Buy
- Analyst Count
- INZY 9
- ACHV 3
- Target Price
- INZY $15.22
- ACHV $14.33
- AVG Volume (30 Days)
- INZY 5.3M
- ACHV 234.9K
- Earning Date
- INZY 05-14-2025
- ACHV 05-13-2025
- Dividend Yield
- INZY N/A
- ACHV N/A
- EPS Growth
- INZY N/A
- ACHV N/A
- EPS
- INZY N/A
- ACHV N/A
- Revenue
- INZY N/A
- ACHV N/A
- Revenue This Year
- INZY N/A
- ACHV N/A
- Revenue Next Year
- INZY N/A
- ACHV N/A
- P/E Ratio
- INZY N/A
- ACHV N/A
- Revenue Growth
- INZY N/A
- ACHV N/A
- 52 Week Low
- INZY $0.72
- ACHV $1.84
- 52 Week High
- INZY $6.24
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- INZY 85.93
- ACHV 69.97
- Support Level
- INZY $3.94
- ACHV $2.89
- Resistance Level
- INZY $3.97
- ACHV $3.32
- Average True Range (ATR)
- INZY 0.08
- ACHV 0.25
- MACD
- INZY 0.12
- ACHV 0.06
- Stochastic Oscillator
- INZY 99.32
- ACHV 95.12
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.